Recombinant human thrombopoietin is generally effective in 7 to 10 days. The life cycle of normal platelets is 7 to 10 days, after the application of recombinant human thrombopoietin, it takes 7 to 10 days for the newly generated platelets to be released into the peripheral blood, which is mainly used for the adjuvant treatment of chemotherapy-induced thrombocytopenia and idiopathic thrombocytopenic purpura. Generally, the drug should be used continuously for 14 days and should be discontinued when the platelet count recovers to more than 100×10^9/L or when it has been used for 14 days and the absolute value of the platelet count is elevated by ≥50×10^9/L. Monitor blood counts and peripheral blood smears regularly during the course of administration, and terminate treatment with this product if new cytomorphologic abnormalities or aggravation of pre-existing cytomorphologic abnormalities are detected. Overuse or routine use in atopic individuals may cause excessive elevation of platelets and should be used appropriately under medical supervision.